Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Hold at Zacks Research

Posted by Renee Jackson on Dec 4th, 2025

Zacks Research upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT – Free Report) to a hold rating in a research report released on Tuesday,Zacks.com reports.

Several other research firms have also recently weighed in on IKT. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

View Our Latest Report on IKT

Inhibikase Therapeutics Trading Up 2.1%

IKT opened at $1.44 on Tuesday. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $4.20. The firm has a market cap of $108.26 million, a P/E ratio of -3.69 and a beta of 0.88. The firm has a 50 day moving average of $1.56.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Inhibikase Therapeutics Company Profile

(Get Free Report)

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.